About Anthem Biosciences Limited
Data last updated: 08 January 2026
Anthem Biosciences Limited is a public limited company based in Bangalore, Karnataka, India. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 13 June 2006, the company has been in operation for over 20 years.
Registered with ROC Bangalore under CIN U24233KA2006PTC039703. Listed.
Capital: an authorised share capital of ₹125 Cr and a paid-up capital of ₹112.32 Cr. It is led by directors including Ganesh Sambasivam and Ajay Bhardwaj.
Last AGM: 10 June 2025. Financial statements filed for year ended 31 March 2025. Office: Bangalore, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,930.28 Cr, a growth of 30% compared to the previous year.
The company has a workforce of approximately 1,876 employees as per the latest available data.
The company is associated with 1 brand - Anthem Biosciences. As per MCA filings, the company has open charges of ₹311.21 Cr and satisfied charges of ₹484.38 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website anthembio.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressNo. 49 F1 & F2 Canara Bank Road Bommasandra Industrial Area Phase I Bo, Mmasandra, Bangalore, Karnataka, India – 560099
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Anthem Biosciences Limited
Anthem Biosciences Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24233KA2006PLC039703, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24233KA2006PLC039703 | Current |
| U24233KA2006PTC039703 | Previous |
| U24233KA2006PLC039703 | Previous |
Associated Brands with Anthem Biosciences Limited
Anthem Biosciences Limited operates one associated brand: Anthem Biosciences. These brands represent Anthem Biosciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Developer of integrated contract research development and manufacturing services | anthembio.com |
Competitors & Alternatives of Anthem Biosciences Limited
Brands and companies operating in the same space as Anthem Biosciences Limited include Abzena, Syngene, Grand River Aseptic Manufacturing and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Abzena
|
Provider of antibody discovery, cell line development, and bio analytics services | Cambridge, United Kingdom, United Kingdom | 2001 |
Syngene
|
Provider of contract research and manufacturing services for both small molecules and biologics | Bengaluru, India, India | 1993 |
Grand River Aseptic Manufacturing
|
Sterile parenteral CDMO services for development and manufacturing are offered. | Grand Rapids, United States, United States | 2010 |
Patheon
|
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry | Durham, United States, United States | 1974 |
Panacea Biotec
|
Developer of biosimilars, vaccines and natural products | Ambala, India, India | 1984 |
Piramal Group
|
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | Mumbai, India, India | 1984 |
Maravai Life Sciences
|
Provides enabling tools and services in the life sciences research and bio-production industries | San Diego, United States, United States | 2014 |
LakePharma
|
Provider of drug discovery on molecular biology, viral vectors and cell & protein engineering | Belmont, United States, United States | 2009 |
Insud Pharma
|
Finished formulations, APIs, and monoclonal antibodies are developed and manufactured. | Madrid, Spain, Spain | 1977 |
Business Activity of Anthem Biosciences Limited
Anthem Biosciences Limited is engaged in principal business activities including manufacturing and professional, scientific and technical, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, scientific research and development. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Board of Directors of Anthem Biosciences Limited
Anthem Biosciences Limited is currently managed by 11 directors, with 3 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ganesh Sambasivam | Whole-Time Director | 04 Aug 2006 | 19 Years 11 Months | Current |
| Ajay Bhardwaj | Managing Director | 13 Jun 2006 | 20 Years 0 Months | Current |
| Shubha Kulkarni | Director | 27 Sep 2024 | 1 Years 9 Months | Current |
|
K Ravindra Chandrappa
Also directs:
Neoanthem Lifesciences Private Limited, Kcr Ventures Llp, Ravisika Hospitality Llp and 1 more
|
Whole-Time Director | 27 Sep 2006 | 19 Years 9 Months | Current |
|
Ramadurai Ramesh
Also directs:
3M India Limited
|
Director | 27 Sep 2024 | 1 Years 9 Months | Current |
| Satish Chander Subbanna | Nominee Director | 09 Apr 2021 | 5 Years 3 Months | Current |
Financials of Anthem Biosciences Limited FY 2025 filings available
Anthem Biosciences Limited reported revenue of ₹1,930.28 Cr (up 30% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Anthem Biosciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Sep 2022 | Citi Bank N.A. | ₹125 Cr | Open |
| 16 May 2017 | Hdfc Bank Limited | ₹25 Cr | Open |
| 14 Feb 2017 | Others | ₹11.21 Cr | Open |
| 26 May 2014 | Citi Bank N.A. | ₹150 Cr | Open |
| 16 Feb 2023 | Others | ₹204 Cr | Satisfied |
Total charge records: 14 View all charges
Employees and EPFO Compliance at Anthem Biosciences Limited
View historical data on people associated with Anthem Biosciences Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Anthem Biosciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Anthem Biosciences Limited
GSTIN & GST Filing Data of Anthem Biosciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Anthem Biosciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Anthem Biosciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Anthem Biosciences Limited
MSME Payment Delays by Anthem Biosciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Anthem Biosciences Limited
Subsidiaries & Group Companies of Anthem Biosciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Anthem Biosciences Limited with ownership details.
MCA Filings & Documents of Anthem Biosciences Limited
MCA Filings & Documents of Anthem Biosciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Anthem Biosciences Limited
Recent News on Anthem Biosciences Limited
Frequently Asked Questions about Anthem Biosciences Limited
Anthem Biosciences Limited is an active public limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 13 June 2006 (20+ years old) and is registered under CIN L24233KA2006PLC039703. The company has 1,876 employees.
Anthem Biosciences Limited reported revenue of ₹1,930.28 Cr for FY 2025 (up 30.00% YoY).
The current directors of Anthem Biosciences Limited are:
- Ganesh Sambasivam
- Ajay Bhardwaj
- Shubha Kulkarni
- K Ravindra Chandrappa
- Ramadurai Ramesh
- Satish Chander Subbanna
- Subramanian Madhavan
- Ravikant Uppal
- Ajay Bhardwaj
- Divya Prasad
- Mohammed Gawir Baig
The primary industry of Anthem Biosciences Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Yes, Anthem Biosciences Limited is a listed company.
Anthem Biosciences Limited can be reached at the registered office: No. 49 F1 & F2 Canara Bank Road Bommasandra Industrial Area Phase I Bo, Mmasandra, Bangalore, Karnataka, India – 560099, or through the website anthembio.com.